Randomized Study of Maintenance Therapy With MGN1703 in Patients With SCLC
Status:
Completed
Trial end date:
2017-10-05
Target enrollment:
Participant gender:
Summary
Evaluation of efficacy and safety of MGN1703 administered twice weekly subcutaneously (SC) as
maintenance treatment in patients with extensive disease small cell lung cancer (SCLC) who
achieved at least a partial response (PR) following platinum-based first-line therapy.